Efficacy of Trimetazidine in Limiting Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis

Angiology ◽  
2021 ◽  
pp. 000331972098774
Author(s):  
Chang Wang ◽  
Weiwei Chen ◽  
Ming Yu ◽  
Ping Yang
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Myocardial Injury ◽  
Meta Analysis ◽  
Coronary Intervention ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Current Evidence ◽  
Percutaneous Coronary ◽  
Significant Difference ◽  
Periprocedural Myocardial Injury

We systematically searched the literature to assess the efficacy of trimetazidine in reducing periprocedural myocardial injury and improving postoperative left ventricular ejection fraction (LVEF) in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). An electronic search was conducted based on the PubMed, Ovid, Scopus, Springer, CENTRAL, and Google Scholar databases; 14 randomized controlled trials (RCTs) were included. Our meta-analysis showed a significant reduction in cardiac troponin I (cTnI) levels with trimetazidine compared with controls ( P < .00001) but not in serum creatine kinase-myocardial band levels ( P = .49). There were significantly reduced odds of ischemic ST-T segment changes with trimetazidine ( P = .0.03) but lack of significant difference in the incidence of anginal attacks between the 2 groups ( P = .10). Results also suggest significantly higher LVEF with trimetazidine compared with controls ( P < .00001). Meta-regression analysis indicated no influence of duration of trimetazidine therapy on cTnI levels. The administration of preprocedure trimetazidine may have a role in reducing periprocedural myocardial injury in patients with CAD undergoing PCI. Evidence also suggests that postoperative trimetazidine may improve LVEF in the short term. Lack of high-quality trials and the heterogeneity of studies limit the ability of our analysis to draw strong conclusions. Further well-designed RCTs are required to supplement current evidence.

Nicorandil for Periprocedural Myocardial Injury in Elective Percutaneous Coronary Intervention: A Meta-Analysis of 10 Randomized Controlled Trials

Angiology ◽  
2020 ◽  
Vol 71 (7) ◽  
pp. 609-615
Author(s):  
Bin Yi ◽  
Jinwen Luo ◽  
Yumei Jiang ◽  
Shaoyan Mo ◽  
Xiaoyi Xiao ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Randomized Controlled Trials ◽  
Myocardial Injury ◽  
Meta Analysis ◽  
Coronary Intervention ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Percutaneous Coronary ◽  
Periprocedural Myocardial Injury

The clinical outcomes of nicorandil in percutaneous coronary intervention (PCI) are conflicting. We sought to evaluate the effects of nicorandil on periprocedural myocardial injury (PMI) in elective PCI. Eligible studies that reported the effect of nicorandil on PMI in elective PCI were obtained from PubMed, Web of Science, and Cochrane Library (up to October 28, 2019). The outcomes were PMI and major adverse cardiovascular and cerebrovascular events (MACCEs). Ten randomized controlled trials with 1304 patients undergoing elective PCI were evaluated. Nicorandil significantly reduced the incidence of PMI (odds ratio [OR] = 0.48; P = .0003); however, there was no significant difference in MACCEs (OR = 0.80; P = .45) between the 2 groups. Subgroup analyses showed that nicorandil significantly lowered the PMI risk when only patients with stable coronary artery disease (OR = 0.41; P = .0008) were considered and when nicorandil was administered intravenously (OR = 0.41; P = .0007) or orally (OR = 0.33; P = .0001). This meta-analysis suggests that nicorandil could reduce the incidence of PMI without increasing the occurrence of MACCEs in elective PCI. The effect of nicorandil in lowering the PMI risk is associated with the diagnosis of the patients and the route of nicorandil administration.

Abstract 241: Incidence of Definite Stent Thrombosis in Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention and Therapeutic Hypothermia - Preliminary Results

Circulation ◽  
2018 ◽  
Vol 138 (Suppl_2) ◽  
Author(s):  
Martin Rauber ◽  
Philipp Nicol ◽  
Michael Joner ◽  
Matjaz Bunc ◽  
Marko Noc
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Cardiac Arrest ◽  
Therapeutic Hypothermia ◽  
Stent Thrombosis ◽  
Coronary Intervention ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Percutaneous Coronary ◽  
Significant Difference ◽  
Hospital Cardiac Arrest

Background: Immediate percutaneous coronary intervention (PCI) is increasingly performed in comatose survivors of out-of-hospital cardiac arrest (OHCA) undergoing therapeutic hypothermia (TH). Since reported incidence of stent thrombosis (ST) varies significantly from 2.5% to 31%, we investigated definite ST using systematic coronary angiography (CAG) and autopsy. Methods: Consecutive comatose survivors of OHCA undergoing immediate PCI and TH admitted between August 2016 and May 2018 were investigated. CAG was performed if ST was suspected and systematically between day 10-14. Patients who died underwent autopsy with analysis of stented segments. Results: Among 147 consecutive patients, immediate CAG was performed 103 (70%) and 52 (50%) underwent PCI. Since 5 patients refused to participate or had no follow-up, 47 patients were included. Definite ST, which was confirmed 8 patients (17%), was diagnosed either by clinically-driven CAG (n = 6), routine CAG (n = 1) or autopsy (n = 1). Patients with ST had more often diabetes (38% vs. 5%; p = 0.008), longer interval of prehospital resuscitation (12.6 ± 10.7 minutes vs. 25.0 ± 10.6 minutes; p = 0.005), higher admission lactate (6.8 ± 6.3 mmol/L vs. 3.2 ± 2.9 mmol/L; p = 0.013), lower arterial pH (7.13 + 0.19 vs. 7.27 ± 0.11; p = 0.005) and less favorable survival with good neurological outcome - Cerebral Performance Category score 1 - 2 (13% vs. 62%; p = 0.03). There was no difference in left ventricular ejection fraction (40 ± 12% vs. 39 ± 13%; p = 0.85), periprocedural dose of unfractioned heparin (8944 ± 2504 IU/kg vs. 8188 ± 2764 IU/kg; p = 0.45), use of GP llb/llla (16 % vs. 25 %; p = 0.59) and of novel P2Y12 inhibitor ticagrelor (79% vs. 63%; p = 0.33). There was no significant difference in total length of stented segment (32.7 ± 24.4 mm vs. 36.6 ± 20.7 mm; p = 0.68) nor in average stent diameter (3.1 ± 0.5 mm vs. 3.2 ± 0.4 mm; p = 0.62). Conclusions: Incidence of definite ST in comatose survivors of OHCA undergoing immediate PCI and TH is significant (17%) and is associated with worse outcome. Prolonged prehospital resuscitation and diabetes rather than PCI characteristics represent the risk factors for development of ST.

Pentraxin Level is the Key to Determine Primary Percutaneous Coronary Intervention (PCI) or Fibrinolysis

2019 ◽  
Vol 19 (2) ◽  
pp. 160-168 ◽  
Author(s):  
Habib Haybar ◽  
Saeed Alipour Parsa ◽  
Isa Khaheshi ◽  
Zeinab Deris Zayeri
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Primary Percutaneous Coronary Intervention ◽  
Coronary Intervention ◽  
Left Ventricular ◽  
Relative Advantage ◽  
Left Ventricular Ejection ◽  
Percutaneous Coronary ◽  
Ptx3 Level ◽  
Tertiary Center ◽  
Functional Advantage

<P>Aims: To examine if pentraxin can help identify patients benefitting most from primary Percutaneous Coronary Intervention (PCI) vs. fibrinolysis. </P><P> Methods: Patients with acute ST-Elevation Myocardial Infarction (STEMI) were consecutively recruited from a community center without PCI and a tertiary center with PCI facilities. Left ventricular ejection fraction (LVEF) was determined echocardiographically at baseline and 5 days after the index admission; the difference between two measurements was considered as the magnitude of improvement. We used regression models to test the hypothesis that the magnitude of the advantage of PCI over fibrinolysis in preserving LVEF 5 days after STEMI is modified by pentraxin 3 (PTX3). </P><P> Results: The functional advantage (LVEF) of the PCI over fibrinolysis has been determined by PTX3. LVEF was attenuated and even reversed as PTX3 level increased. The primary PCI of the participants with less than 7 ng.ml-1 PTX3 level, achieved a clinically significant increase in the LVEF as compared to fibrinolysis. At lower levels of PTX3, PCI shows a conspicuous advantage over fibrinolysis in terms of the probability of developing an LVEF <40%. </P><P> Conclusion: We demonstrated not only the functional advantage of PCI over fibrinolysis performed within the recommended time frames but also the relative advantage of its relevance to the baseline PTX3 levels. PTX3 can play a role in determining the choice of best therapy. More than 75% of patients with STEMI who have PTX3 levels ≤7 ng.ml-1 imply the need of PCI.</P>

scholarly journals Differing effects of beta-blockers on long-term clinical outcomes following percutaneous coronary intervention between patients with mid-range and reduced left ventricular ejection fraction

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jun Shitara ◽  
Ryo Naito ◽  
Takatoshi Kasai ◽  
Hirohisa Endo ◽  
Hideki Wada ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Ejection Fraction ◽  
Clinical Outcomes ◽  
Beta Blockers ◽  
Coronary Intervention ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Coronary Syndrome ◽  
Percutaneous Coronary

Abstract Background The aim of this study was to determine the difference in effects of beta-blockers on long-term clinical outcomes between ischemic heart disease (IHD) patients with mid-range ejection fraction (mrEF) and those with reduced ejection fraction (rEF). Methods Data were assessed of 3508 consecutive IHD patients who underwent percutaneous coronary intervention (PCI) between 1997 and 2011. Among them, 316 patients with mrEF (EF = 40–49%) and 201 patients with rEF (EF < 40%) were identified. They were assigned to groups according to users and non-users of beta-blockers and effects of beta-blockers were assessed between mrEF and rEF patients, separately. The primary outcome was a composite of all-cause death and non-fatal acute coronary syndrome. Results The median follow-up period was 5.5 years in mrEF patients and 4.3 years in rEF patients. Cumulative event-free survival was significantly lower in the group with beta-blockers than in the group without beta-blockers in rEF (p = 0.003), whereas no difference was observed in mrEF (p = 0.137) between those with and without beta-blockers. In the multivariate analysis, use of beta-blockers was associated with reduction in clinical outcomes in patients with rEF (hazard ratio (HR), 0.59; 95% confidence interval (CI), 0.36–0.97; p = 0.036), whereas no association was observed among those with mrEF (HR 0.74; 95% CI 0.49–1.10; p = 0.137). Conclusions Our observational study showed that use of beta-blockers was not associated with long-term clinical outcomes in IHD patients with mrEF, whereas a significant association was observed in those with rEF.

scholarly journals Contrast Volume/Raw eGFR Ratio for Predicting Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention for Myocardial Infarction

2015 ◽  
Vol 5 (1) ◽  
pp. 61-68 ◽  
Author(s):  
Hoon Suk Park ◽  
Chan Joon Kim ◽  
Jeong-Eun Yi ◽  
Byung-Hee Hwang ◽  
Tae-Hoon Kim ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Kidney Injury ◽  
Percutaneous Coronary Intervention ◽  
Roc Curve ◽  
Kidney Injury ◽  
Coronary Intervention ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Contrast Volume ◽  
Percutaneous Coronary

Background: Considering that contrast medium is excreted through the whole kidney in a similar manner to drug excretion, the use of raw estimated glomerular filtration rate (eGFR) rather than body surface area (BSA)-normalized eGFR is thought to be more appropriate for evaluating the risk of contrast-induced acute kidney injury (CI-AKI). Methods: This study included 2,189 myocardial infarction patients treated with percutaneous coronary intervention. Logistic regression analysis was performed to identify the independent risk factors. We used receiver-operating characteristic (ROC) curves to compare the ratios of contrast volume (CV) to eGFR with and without BSA normalization in predicting CI-AKI. Results: The area under the curve (AUC) of the ROC curve for the model including all the significant variables such as diabetes mellitus, left ventricular ejection fraction, preprocedural glucose, and the CV/raw modification of diet in renal disease (MDRD) eGFR ratio was 0.768 [95% confidence interval (CI), 0.720-0.816; p < 0.001]. When the CV/raw MDRD eGFR ratio was used as a single risk value, the AUC of the ROC curve was 0.650 (95% CI, 0.590-0.711; p < 0.001). When the CV/MDRD eGFR ratio with BSA normalization ratio was used, the AUC of the ROC curve further decreased to 0.635 (95% CI, 0.574-0.696; p < 0.001). The difference between the two AUCs was significant (p = 0.002). Conclusions: Raw eGFR is a better predictor for CI-AKI than BSA-normalized eGFR.

scholarly journals Successful extracorporeal membrane oxygenation assisted revascularisation in a high-risk elderly patient refused surgical treatment

2020 ◽  
Vol 26 (4) ◽  
pp. 205-210
Author(s):  
Robertas Samalavičius ◽  
Lina Puodžiukaitė ◽  
Vytautas Abraitis ◽  
Ieva Norkienė ◽  
Nadežda Ščupakova ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
High Risk ◽  
Elderly Patients ◽  
Extracorporeal Membrane Oxygenation ◽  
Coronary Intervention ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Uneventful Recovery ◽  
Membrane Oxygenation ◽  
Percutaneous Coronary

Management of high-risk elderly patients requiring revascularisation remains a clinical challenge. We report a case of extracorporeal membrane oxygenation (ECMO) assisted complex percutaneous coronary intervention in a high-risk octogenarian. An 83-yearold female with signs of worsening heart failure was admitted to the emergency department of a tertiary care facility. Transthoracic echocardiography revealed a decreased left ventricular ejection fraction of 20% with severe mitral regurgitation and mild aortic and tricuspid valve insufficiency. Three-vessel disease was found during coronary angiography. Due to the patient’s frailty, a high-risk surgery decision to proceed with ECMO assisted percutaneous coronary intervention was made during a heart team meeting. Following initiation of mechanical support, coronary lesions were treated with three drug-eluting stents. After the procedure, the patient was transferred to the ICU on ECMO support, where she was successfully weaned from the device 9 h later. Her ICU stay was four days. She was successfully discharged from the hospital after uneventful recovery. At one-year’s follow-up, the patient was clinically stable in an overall state of general well-being and with complete participation in routine activities; she had good exercise tolerance and no signs of ischemia. This report highlights the possibility of use of ECMO during PCI in high-risk elderly patients.

Sign in / Sign up

Export Citation Format

Share Document